Innocan Pharma Reports Success in a Pre-Clinical Trial of a Liposomal-CBD Injection on a Paralyzed Goat
HERZLIYA, Israel and CALGARY, Alberta, May 8, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a leading pharmaceutical and biotech company, is pleased to announce the successful treatment of Billy, a 4-year-old neutered male goat, with a liposomal-CBD injection in a pre-clinical trial. The innovative therapy provided much-needed relief to the animal, born with neurological deficits and scoliosis, resulting in hind-limb paralysis and fore-limb deformity. Scientific research indicates that the success of a pre-clinical trial on large mammals (such as goats) generally infers increased bio-feasibility in similar rates amongst humans. https://youtu.be/MDG0QJc9k50
Billy was adapted to move around with a wheelchair, but as his size and weight increased, his scoliosis worsened, and his activity decreased substantially. Despite being administered non-steroidal anti-inflammatory drugs, the goat's pain persisted, and he was unwilling to move on his wheelchair.
As an act of compassion therapy, Billy was administered a liposomal-CBD injection on top of the drugs he was already taking. The results were almost immediate, with the goat becoming active and playing as he used to do over a year ago. The improvement in Billy's activity lasted for almost 4 weeks.
"Slowly yet surly, Innocan proves its biological standings to be accurate and feasible. We are thrilled to have brought relief to Billy using our innovative liposomal-CBD injection," said Iris Bincovich, CEO of Innocan Pharma. "This is a testament to the potential of our technology to improve the lives of both humans and animals."
Innocan Pharma's liposomal-CBD injection is a unique formulation that allows for targeted delivery of CBD to specific body areas, resulting in enhanced efficacy and reduced side effects. The Company is committed to advancing the development of CBD-based therapeutics for various indications in both humans and animals.
About Innocan
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti- inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
15162104025+
+972-54-3012842
+442037699377
[email protected]
Dr. Eva Reuter
Investment Relation- Germany
+46-69-1532-5857
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Logo - https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
SOURCE Innocan Pharma Corporation
Share this article